Full Product Name
AML1 (Phospho-Ser303) Antibody
Product Synonym Names
CBFA2, EVI-1, AMLCR1, PEBP2aB, AML1-EVI-1
Product Gene Name
anti-AML1 antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q01196
Species Reactivity
Human, Mouse, Rat
Specificity
The antibody detects endogenous level of AML1 only when phosphorylated at Serine 303.
Purity/Purification
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
Form/Format
Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Concentration
1.0 mg/ml (lot specific)
Immunogen Type
Peptide-KLH
Immunogen Description
Peptide sequence around phosphorylation site of serine 303
Modification
Phospho-Ser303
Preparation and Storage
Store at -20 degree C/1 year
Other Notes
Small volumes of anti-AML1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-AML1 antibody
CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B-dependent transcriptional activation.
Product Categories/Family for anti-AML1 antibody
Phospho-specific Ab
Applications Tested/Suitable for anti-AML1 antibody
Western Blot (WB)
Application Notes for anti-AML1 antibody
Western blotting: 1:500~1:1000
Western Blot (WB) of anti-AML1 antibody
Western blot analysis of extracts from JK cells using AML1 (Phospho-Ser303) Antibody.The lane on the right is treated with the antigen-specific peptide.

NCBI/Uniprot data below describe general gene information for AML1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001001890.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001001890.2
[Other Products]
UniProt Primary Accession #
Q01196
[Other Products]
UniProt Secondary Accession #
O60472; O60473; O76047; O76089; Q13081; Q13755; Q13756; Q13757; A8MV94; B2RMS4; D3DSG1[Other Products]
UniProt Related Accession #
Q01196[Other Products]
Molecular Weight
37,733 Da
NCBI Official Full Name
runt-related transcription factor 1 isoform AML1b
NCBI Official Synonym Full Names
runt-related transcription factor 1
NCBI Official Symbol
RUNX1 [Similar Products]
NCBI Official Synonym Symbols
AML1; CBFA2; EVI-1; AMLCR1; PEBP2aB; CBF2alpha; AML1-EVI-1; PEBP2alpha
[Similar Products]
NCBI Protein Information
runt-related transcription factor 1
UniProt Protein Name
Runt-related transcription factor 1
UniProt Synonym Protein Names
Acute myeloid leukemia 1 protein; Core-binding factor subunit alpha-2; CBF-alpha-2; Oncogene AML-1; Polyomavirus enhancer-binding protein 2 alpha B subunit; PEA2-alpha B; PEBP2-alpha B; SL3-3 enhancer factor 1 alpha B subunit; SL3/AKV core-binding factor alpha B subunit
UniProt Gene Name
RUNX1 [Similar Products]
UniProt Synonym Gene Names
AML1; CBFA2; CBF-alpha-2; PEA2-alpha B; PEBP2-alpha B [Similar Products]
UniProt Entry Name
RUNX1_HUMAN
NCBI Summary for AML1
Core binding factor (CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters. The protein encoded by this gene represents the alpha subunit of CBF and is thought to be involved in the development of normal hematopoiesis. Chromosomal translocations involving this gene are well-documented and have been associated with several types of leukemia. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
UniProt Comments for AML1
AML1: CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B- dependent transcriptional activation. Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize. Interacts with TLE1 and ALYREF/THOC4. Interacts with ELF1, ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with KAT6A and KAT6B. Interacts with SUV39H1, leading to abrogation of transactivating and DNA-binding properties of RUNX1. Interacts with YAP1. Interacts with HIPK2. Interaction with CDK6 prevents myeloid differentiation, reducing its transcription transactivation activity. Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood. 11 isoforms of the human protein are produced by alternative splicing.
Protein type: DNA-binding; Transcription factor; Oncoprotein
Chromosomal Location of Human Ortholog: 21q22.3
Cellular Component: nucleoplasm; intracellular membrane-bound organelle; cytoplasm; basement membrane; nucleus
Molecular Function: protein binding; protein homodimerization activity; DNA binding; protein heterodimerization activity; calcium ion binding; transcription factor binding; transcription factor activity; ATP binding
Biological Process: central nervous system development; hair follicle morphogenesis; transcription, DNA-dependent; embryonic hemopoiesis; in utero embryonic development; positive regulation of transcription, DNA-dependent; positive regulation of granulocyte differentiation; regulation of signal transduction; liver development; negative regulation of granulocyte differentiation; peripheral nervous system neuron development; behavioral response to pain; positive regulation of angiogenesis; myeloid progenitor cell differentiation; positive regulation of interleukin-2 production; hemopoiesis; myeloid cell differentiation; positive regulation of transcription from RNA polymerase II promoter; skeletal development
Disease: Platelet Disorder, Familial, With Associated Myeloid Malignancy; Leukemia, Acute Myeloid; Rheumatoid Arthritis
Research Articles on AML1
1. Low expression of Runx1 along with reduced proportion of Treg in CD4(+) T cells may be associated with development of systemic sclerosis even in early disease.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.